SCHEMBL5651710

SCHEMBL5651710

CCOC(=O)c1sc2c(ccc(=O)n2-c2cccnc2)c1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 3/20 0.46
POLB P06746 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
CDC7 O00311 4/20 0.44
DBF4 Q9UBU7 4/20 0.44
ALDH1A1 P00352 5/20 0.43
TP53 P04637 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651778 0.94 MEN1 (0.48) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5650136 0.90 MAPT (0.51) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL2780006 0.86 ALDH1A1 (0.43) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL2781810 0.85 MEN1 (0.44) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5653998 0.85 MAPT (0.48) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5650867 0.85 MAPT (0.47) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5651739 0.84 ALDH1A1 (0.44) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5652764 0.84 MAPT (0.45) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5652595 0.84 MAPT (0.45) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5653063 0.83 ALDH1A1 (0.52) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MEN1 4697/4885KMT2A 1815/4885NPC1 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.